Pulmatrix, Inc.
Close on Oct 19, 2026
- Market cap
- $5.19M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 15, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 16, 2025 | Before market open | $0 | $-0.24 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $0 | $-0.42 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 21, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | $400.00K | $-0.71 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | $1.60M | $-1.59 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | $5.90M | $0.23 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | – | – | – |
Press releases
Announcements Pulmatrix filed with the SEC
Announces Second Quarter 2026 Financial Results and Progress on Merger
Results of operations · EX-99.1 to Form 8-K
Announces First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Year-End and Fourth Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
Results of operations · EX-99.1 to Form 8-K
Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
Results of operations · EX-99.1 to Form 8-K
Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
Results of operations · EX-99.1 to Form 8-K
and Cullgen Announce Proposed Merger
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
NOVEMBER 2024 [To be released at 12 PM Eastern time]
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve
Material agreement · Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Announces First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
to Host Key Opinion Leader Webinar “PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment”
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
Regulation FD disclosure · EX-99.1 to Form 8-K
Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Announces First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K